carbons together with scaffold hopping, we designed and synthesized two new series of thieno[2,3-d]pyrimidine and thiazolo[5,4-d]pyrimidine derivatives for use as PI3K inhibitors. Our structure–activity relationship studies led to the identification of thieno[2,3-d]pyrimidine 6a and thiazolo[5,4-d]pyrimidine 7a, which exhibited remarkable nanomolar PI3K potency, good antiproliferative activity, favorable
由于
PI3K信号异常是许多类型癌症的特征,因此口服活性
PI3K
抑制剂的开发对于靶向癌症治疗具有重要意义。通过整合降低芳族特性/增加sp 3碳含量的策略以及支架跳跃,我们设计并合成了两个新系列的
噻吩并[2,3-d]
嘧啶和
噻唑并[5,4-d]
嘧啶衍
生物。作为
PI3K
抑制剂。我们的结构-活性关系研究导致了
噻吩并[2,3-d]
嘧啶6a和
噻唑并[5,4-d]
嘧啶7a的鉴定,其表现出显着的纳摩尔
PI3K效力,良好的抗增殖活性,良好的药代动力学特性和显着的体内抗癌功效。值得注意的是,与
噻吩并[2,3-d]
嘧啶6a相比,
噻唑并[5,4-d]
嘧啶7a具有更好的抗癌活性和类药物特性,值得进一步临床前评估其在癌症治疗中的用途。